Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement

FDA Warning Letters: GLP-1 Medications

Register of FDA warning letters issued concerning GLP-1 medications (semaglutide, tirzepatide) (Source: FDA Inspections & Compliance, data through Nov 5, 2026).

Regulatory & Editorial Notice:

This register reproduces official regulatory enforcement records published by the FDA at the time of issuance. Addressed establishments may have since implemented corrective actions or entered compliance agreements with regulatory authorities. For subsequent remedial filings or official closeout letter status, refer directly to FDA.gov.

162

Verified Warning Letters

130

Establishments with Full Address

2023–2026

Chronological Coverage

GLP-1 FDA Warning Letters Data Summary & CSV Export

Explore aggregate counts by calendar year, active ingredient, violation categories, and recipient entity type, or download the full open CSV dataset.

View Data Summary →
Showing 162 of 162 warning letters

www.buynetmeds.com

2025-06-12Center for Drug Evaluation and Research (CDER)
FDA.gov
Active ingredients:RetatrutideSemaglutideOther Facility

FDA says the website introduces into interstate commerce unapproved and misbranded semaglutide drug products, including injectable versions.

RonanRx, Inc. dba RonanRx

2026-10-30Center for Drug Evaluation and Research (CDER)1011 Old McDade Rd. Elgin, TX 78621, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the company's website and X posts made false or misleading claims that its compounded semaglutide and tirzepatide were FDA-approved, well-studied, American made, and farm-to-table, and that product labels suggested RonanRx was the compounder of those drugs "when in fact it is not."

Cheap Medicine Shop/www.cheapmedicineshop.com

2026-09-24Center for Drug Evaluation and Research (CDER)
FDA.gov
Active ingredients:SemaglutideOnline / Internet Pharmacy

FDA found www.cheapmedicineshop.com introducing unapproved and misbranded injectable semaglutide ("Semanext Injection") into interstate commerce without an approved application or adequate directions for use.

Online Generic Medicine/www.onlinegenericmedicine.com

2026-09-23Center for Drug Evaluation and Research (CDER)
FDA.gov
Active ingredients:SemaglutideOnline / Internet Pharmacy

FDA says the website introduced unapproved and misbranded injectable semaglutide (Semanat Injection) into interstate commerce without FDA approval, adequate directions, or required prescription, violating FD&C Act sections 301, 502(f)(1), 503(b)(1), and 505(a).

Empower Clinic Services, LLC dba Empower Pharmacy

2026-09-18Center for Drug Evaluation and Research (CDER)7601 N. Sam Houston Pkwy W., Ste. 100, Houston, TX 77064-3595, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideCompounding pharmacy

FDA says the firm compounded semaglutide and tirzepatide products that "appear to be essentially copies" of FDA-approved drugs regularly and in inordinate amounts without valid individualized prescriber determinations, and prepared sterile products under insanitary conditions with significant CGMP violations.

TXP Innovations LLC dba Tex Peptides

2026-08-24Center for Drug Evaluation and Research (CDER)539 West Commerce Street, Dallas, TX 75208-1953, United States
FDA.gov
Active ingredients:RetatrutideSemaglutideTirzepatideOther Facility

FDA's July 2026 review of texpeptide.com found seven products, including semaglutide, tirzepatide, and retatrutide, to be unapproved new drugs offered without approved applications, violating FD&C Act sections 301(d) and 505(a).

Royal Peptides LLC

2026-08-24Center for Drug Evaluation and Research (CDER)2310 SE 2nd St. Ste 7, Boynton Beach, FL 33435, United States
FDA.gov
Active ingredients:RetatrutideSemaglutideTirzepatideOther Facility

FDA says the website review found Tirzepatide, Semaglutide, Retatrutide, SS-31, PT-141, Tesamorelin, and BIMORELIN marketed as unapproved new drugs with drug-intended labeling; introducing them into interstate commerce violates FD&C Act sections 301(d) and 505(a).

NuScience Peptides LLC

2026-08-24Center for Drug Evaluation and Research (CDER)20311 Chartwell Center Dr., Suite 212, Cornelius, NC 28031, United States
FDA.gov
Active ingredients:MazdutideRetatrutideSemaglutideSurvodutideTirzepatideOther Facility

An FDA website review found nine products, including GLP-1 peptides and bacteriostatic water, are unapproved new drugs lacking approved applications; introducing them into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.

Peptide Partners LLC

2026-08-24Center for Drug Evaluation and Research (CDER)8350 Bee Ridge, #379, Sarasota, FL 34241-9607, United States
FDA.gov
Active ingredients:RetatrutideSemaglutideTirzepatideOther Facility

FDA says the firm marketed seven unapproved new drug products, including semaglutide, tirzepatide, and retatrutide peptides, on its website with claims of treating disease and affecting body function, without FDA-approved applications.

Peak Performance Peptides

2026-08-24Center for Drug Evaluation and Research (CDER)3935 E Rough Rider Rd Unit 1016, Phoenix, AZ 85050, United States
FDA.gov
Active ingredients:RetatrutideSemaglutideOther Facility

FDA found Bac water, GLP-3R (retatrutide), Semaglutide, SS-31, PT-141, and Tesamorelin to be unapproved new drugs marketed without approved applications, citing website labeling claims and interstate commerce violations.

BioDrive, Inc.

2026-08-24Human Foods Program325 Hudson Street, 4th Floor, New York, NY 10013, United States
FDA.gov
Active ingredients:SemaglutideOther Facility

FDA says Evolv GLP-1 Biomimetic contains EV1-Peptide, a new dietary ingredient with inadequate safety information and potential toxicity concerns; FDA deemed it adulterated under section 402(f)(1)(B) despite two NDIN objections.

Maximus Health, Inc. dba Maximus

2026-06-08Center for Drug Evaluation and Research (CDER)2219 Main Street, #347 Santa Monica, CA 90405 United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website made false or misleading claims that compounded semaglutide and tirzepatide products were clinically studied, proven to lose weight, and sourced from FDA-approved pharmacies; compounded products are not FDA-approved.

Trinity HealthCare Supply, LLC dba altRx

2026-06-08Center for Drug Evaluation and Research (CDER)3206 NE 2nd Ave, Suite 3013, Miami, FL 33137, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website labels pictured compounded semaglutide and tirzepatide as 'altRx' though altRx is not the compounder, and claims such products are 'clinically proven,' implying FDA approval or evaluation they lack.

Glow Medispa, LLC dba Mint Med

2026-06-08Center for Drug Evaluation and Research (CDER)8833 Chapel Square Dr., Cincinnati, OH 45249, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website's compounded semaglutide and tirzepatide labels name Mint Med as compounder when it is not, making the products misbranded under FD&C Act sections 502(a) and 502(bb).

Ezra Holdco LLC dba Ezra

2026-06-08Center for Drug Evaluation and Research (CDER)30 N Gould St. Suite 63027, Sheridan, WY 82801, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website offers compounded semaglutide and tirzepatide labeled "Ezra," falsely suggesting Ezra is the compounder, making the products misbranded under FD&C Act sections 502(a) and 502(bb).

Public Health Solution LLC dba DrMedHealth

2026-06-08Center for Drug Evaluation and Research (CDER)2003 Plank Road, #1283 Fredericksburg, VA 22401 United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website claims compounded semaglutide and tirzepatide products have the "same active ingredient as Ozempic and Mounjaro," implying FDA approval or evaluation for safety and effectiveness, misbranding them under FD&C Act sections 502(a) and 502(bb).

D&H Medical Services

2026-06-08Center for Drug Evaluation and Research (CDER)2500 NW 79th Avenue, Suite 265, Doral, FL 33122, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website claims compounded semaglutide and tirzepatide products are 'Same ingredient as Ozempic, Rybelsus, Mounjaro,' implying FDA approval or evaluation when compounded drugs are not FDA-approved, misbranding them under FD&C Act sections 502(a) and 502(bb).

Amie Health, Inc. dba Amie

2026-06-08Center for Drug Evaluation and Research (CDER)382 NE 191st St., Suite 35622, Miami, FL 33179, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website labeled compounded semaglutide and tirzepatide products with 'amie,' falsely suggesting Amie is the compounder, and claimed they contain the same active ingredients as Ozempic, Mounjaro, and Wegovy and use FDA-approved active ingredients, though compounded drugs are not FDA-approved.

Altru Telehealth, LLC dba Altru Telehealth

2026-06-08Center for Drug Evaluation and Research (CDER)5000 Thayer Center, Oakland, MD 21550, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website falsely claimed compounded semaglutide and tirzepatide are FDA-approved, and that compounding pharmacies are FDA-approved or FDA-licensed, misbranding the products.

Eden Health International Inc. dba Eden

2026-06-08Center for Drug Evaluation and Research (CDER)110 16th St Ste 1431, Denver, CO 80202, United States
FDA.gov
Active ingredients:SemaglutideTirzepatideTelehealth

FDA says the website falsely suggests Eden compounds semaglutide and tirzepatide and claims products come from “FDA-licensed 503(a) outsourcing facilities”; FDA states compounders are not FDA-approved or licensed, causing misbranding.

Page 1 of 9

Complete Archive by Year

Chronological index of all 162 verified warning letters issued concerning GLP-1 compounding and promotion.

162 Verified Records

2026 Warning Letters

78 letters

2025 Warning Letters

71 letters